Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Capital Expenditures (2016 - 2024)

Historic Capital Expenditures for Theravance Biopharma (TBPH) over the last 12 years, with Q4 2024 value amounting to $190000.0.

  • Theravance Biopharma's Capital Expenditures fell 7193.5% to $190000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $241000.0, marking a year-over-year decrease of 7057.39%. This contributed to the annual value of $332000.0 for FY2024, which is 8665.59% down from last year.
  • As of Q4 2024, Theravance Biopharma's Capital Expenditures stood at $190000.0, which was down 7193.5% from $15000.0 recorded in Q3 2024.
  • In the past 5 years, Theravance Biopharma's Capital Expenditures registered a high of $2.4 million during Q2 2020, and its lowest value of -$57000.0 during Q3 2022.
  • Moreover, its 5-year median value for Capital Expenditures was $355000.0 (2021), whereas its average is $670700.0.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 256233.77% in 2020, then plummeted by 10548.6% in 2022.
  • Over the past 5 years, Theravance Biopharma's Capital Expenditures (Quarter) stood at $1.2 million in 2020, then tumbled by 64.31% to $444000.0 in 2021, then crashed by 40.09% to $266000.0 in 2022, then skyrocketed by 154.51% to $677000.0 in 2023, then plummeted by 71.94% to $190000.0 in 2024.
  • Its last three reported values are $190000.0 in Q4 2024, $15000.0 for Q3 2024, and $36000.0 during Q2 2024.